DERM Quote, Financials, Valuation and Earnings

Fortress Biotech has a net margin of 11.17% compared to Journey Medical's net margin of -87.96%. Journey Medical's return on equity of -97.05% beat Fortress Biotech's return on equity of --.

Journey Medical has a consensus price target of $9.88, signalling upside risk potential of 59.02%. On the other hand Fortress Biotech has an analysts' consensus of $15.33 which suggests that it could grow by 922.22%. Given that Fortress Biotech has higher upside potential than Journey Medical, analysts believe Fortress Biotech is more attractive than Journey Medical.

Journey Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Fortress Biotech has a beta of 1.825, suggesting its more volatile than the S&P 500 by 82.547%.

Journey Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortress Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical pays -- of its earnings as a dividend. Fortress Biotech pays out -10.24% of its earnings as a dividend.

Journey Medical quarterly revenues are $13.6M, which are smaller than Fortress Biotech quarterly revenues of $14.6M. Journey Medical's net income of $1.5M is higher than Fortress Biotech's net income of -$12.9M. Notably, Journey Medical's price-to-earnings ratio is -- while Fortress Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical is 2.26x versus 0.42x for Fortress Biotech. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of 11.17% compared to Journey Medical's net margin of -49.65%. Journey Medical's return on equity of -97.05% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Journey Medical has a consensus price target of $9.88, signalling upside risk potential of 59.02%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 44.56%. Given that Journey Medical has higher upside potential than NovaBay Pharmaceuticals, analysts believe Journey Medical is more attractive than NovaBay Pharmaceuticals.

Journey Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

Journey Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Journey Medical quarterly revenues are $13.6M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Journey Medical's net income of $1.5M is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Journey Medical's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical is 2.26x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of 11.17% compared to Journey Medical's net margin of --. Journey Medical's return on equity of -97.05% beat Palatin Technologies's return on equity of --.

Journey Medical has a consensus price target of $9.88, signalling upside risk potential of 59.02%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1557.59%. Given that Palatin Technologies has higher upside potential than Journey Medical, analysts believe Palatin Technologies is more attractive than Journey Medical.

Journey Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

Journey Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Journey Medical quarterly revenues are $13.6M, which are larger than Palatin Technologies quarterly revenues of --. Journey Medical's net income of $1.5M is higher than Palatin Technologies's net income of --. Notably, Journey Medical's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical is 2.26x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Retractable Technologies has a net margin of 11.17% compared to Journey Medical's net margin of -18.58%. Journey Medical's return on equity of -97.05% beat Retractable Technologies's return on equity of -16.83%.

Journey Medical has a consensus price target of $9.88, signalling upside risk potential of 59.02%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Journey Medical has higher upside potential than Retractable Technologies, analysts believe Journey Medical is more attractive than Retractable Technologies.

Journey Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Retractable Technologies has a beta of 2.279, suggesting its more volatile than the S&P 500 by 127.852%.

Journey Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical pays -- of its earnings as a dividend. Retractable Technologies pays out -1.94% of its earnings as a dividend.

Journey Medical quarterly revenues are $13.6M, which are larger than Retractable Technologies quarterly revenues of $10.3M. Journey Medical's net income of $1.5M is higher than Retractable Technologies's net income of -$1.9M. Notably, Journey Medical's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical is 2.26x versus 0.63x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.